Drug Database
AT
atorvastatin + ezetimibe (CKD 391 / CKD391)
✓ ApprovedChong Kun Dang Pharmaceutical · HMGCR · Small Molecule
What is atorvastatin + ezetimibe?
atorvastatin + ezetimibe is a small molecule developed by Chong Kun Dang Pharmaceutical. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | CKD 391, CKD391 |
| Company | Chong Kun Dang Pharmaceutical |
| Drug Class | Small Molecule |
| Molecular Target | HMGCR, NPC1L1 |
| Route | Oral (PO) |
| Status | Approved |
Mechanism of Action
Molecular Targets
atorvastatin + ezetimibe acts on 2 molecular targets:
| HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28) |
| NPC1L1 | NPC1 like intracellular cholesterol transporter 1 (SLC65A2, LDLCQ7) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
atorvastatin + ezetimibe is developed for 2 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Metabolism and nutrition disorders | Hypercholesterolaemia | ✓ Approved |
| Metabolism and nutrition disorders | Hyperlipidaemia | ✓ Approved |
Related Research Articles
Unable to load articles right now.